You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

aggressive Non Hodgkin's Lymphomas treated with moderately emetogenic chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)

Completed
Has Results
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 3, 2022

Aggressive Non-Hodgkin Lymphoma Trial in Italy (Prednisone, Vinorelbine, Etoposide)

Completed
  • Aggressive Non-Hodgkin Lymphoma
  • Brescia, Italy
  • +9 more
Dec 17, 2021

Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +8 more
  • Polatuzumab Vedotin
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)

Completed
Has Results
  • Non-Hodgkin's Lymphoma
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

Active, not recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • fractionated first dose rituximab
  • Geneva, Switzerland
    University Hospital Geneva
Apr 21, 2023

Lymphoma Trial in Canada, United States (biological, drug, procedure, radiation)

Completed
Has Results
  • Lymphoma
  • rituximab
  • +10 more
  • Portland, Oregon
  • +14 more
Jan 29, 2021

AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I DLBCL Trial in United States

Completed
Has Results
  • AIDS-Related Plasmablastic Lymphoma
  • +15 more
  • Montgomery, Alabama
  • +34 more
Feb 23, 2022

Primary CNS Lymphoma Trial in Worldwide (Rituximab, Methotrexate, Procarbazine)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Aarhus, Denmark
  • +34 more
Nov 4, 2022

DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)

Completed
  • Diffuse Large B-Cell Lymphoma
  • High Grade B-Cell Lymphoma
  • Boston, Massachusetts
  • +5 more
Aug 23, 2022

Chemo-induced Nausea and Vomiting Trial in Worldwide (NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1

Recruiting
  • Chemotherapy-induced Nausea and Vomiting
  • NEPA (300mg netupitant/0.5mg palonosetron)
  • +2 more
  • Prague, Czechia
  • +12 more
Nov 8, 2022

Chemo Induced Nausea and Vomiting Trial in Mount Olive (Akynzeo)

Recruiting
  • Chemotherapy Induced Nausea and Vomiting
  • Mount Olive, Alabama
    Rudolph M Navari
Oct 8, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (Standard of Care, JCAR017)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Standard of Care
  • JCAR017
  • Phoenix, Arizona
  • +78 more
Jan 13, 2023

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia Trial in Germany, Italy, Spain

Completed
  • Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
  • Aurich, Germany
  • +59 more
Jun 6, 2022

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)

Recruiting
  • Lymphoma
  • +3 more
  • obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

Not yet recruiting
  • T Cell Lymphoma
  • New Haven, Connecticut
    Yale Smilow Cancer Hospital
Aug 14, 2023

Lymphoma Trial in Germany, Switzerland (biological, drug, radiation)

Completed
  • Lymphoma
  • filgrastim
  • +7 more
  • Aachen, Germany
  • +174 more
May 14, 2021

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

Not yet recruiting
  • Lymphoma, Primary Effusion
  • Daratumumab SC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 23, 2023

Malignant Non-Hodgkin Lymphomas Trial in Berne (CD34+ cell selection)

Active, not recruiting
  • Malignant Non-Hodgkin Lymphomas
  • CD34+ cell selection
  • Berne, Switzerland
    Department for Medical Oncology; University Hospital/Inselspital
Jul 29, 2021

Hodgkin Lymphoma, Adolescent Behavior, Chemo Effect Trial (Description of therapeutical results)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Description of therapeutical results
  • (no location specified)
Dec 15, 2022